logo

For the Inventor, By the Inventor

Kanagawa, Japan

Mamoru Hasegawa

This inventor holds 18 USPTO granted patents, primarily in Humanized Antibodies. Top assignees: Kyowa Hakko Kogyo Co., Ltd., Kyowa Medex Co., Ltd., Meito Sangyo Kabushiki Kaisha. Active years: 1993-2006.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mamoru Hasegawa. Retrieved from https://idiyas.com/inventor/mamoru-hasegawa-r053bl8y

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18

% Patents Active = 83.3

Average Co-Inventor Count = 5.1

ph-index = 10

Forward Citations = 467(Granted Patents)


Location History:

  • Kawasaki, JP (1993 - 1996)
  • Matsudo, JP (1999 - 2001)
  • Kanagawa, JP (1998 - 2006)

Company Filing History:

goldMedal17 out of 730 
 
Kyowa Hakko Kogyo Co., Ltd.
 patents
silverMedal1 out of 69 
 
Kyowa Medex Co., Ltd.
 patents
bronzeMedal1 out of 23 
 
Meito Sangyo Kabushiki Kaisha
 patents
4. 1 out of 834,659 
Other
 patents
where one patent can have more than one assignee

Years Active: 1993-2006

Loading Chart...
Areas of Expertise:
Humanized Antibodies
Chimeric Antibody
Ganglioside GD3
Ganglioside GM2
Cancer Treatment
Polypeptide
DNA Encoding
Sialyltransferase
Neuraminidase
Porphyromonas Gingivalis
Host Cells
18 patents (USPTO):Explore Patents
1. 7045129 - Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3 (2006-05-16),
2. 6965024 - Process for producing humanized chimera antibody (2005-11-15),
3. 6872392 - Humanized antibodies (2005-03-29),
4. 6495666 - Polypeptide composing human chimeric antibody (2002-12-17),
5. 6437098 - Human chimeric antibody specific for the ganglioside GD3 (2002-08-20),
6. 6423511 - Humanized antibodies (2002-07-23),
7. 6171805 - DNA and host cells encoding a cell surface protein of Porphyromonas gingivalis (2001-01-09),
8. 6042828 - Humanized antibodies to ganglioside GM.sub.2 (2000-03-28),
9. 5948636 - DNA and host cells encoding a cell surface protein of porphyromonas (1999-09-07),
10. 5939532 - Humanized antibodies to ganglioside GM.sub.2 (1999-08-17),
11. 5874255 - DNA encoding humanized antibodies specific for the ganglioside GM.sub.2 (1999-02-23),
12. 5866692 - Process for producing humanized chimera antibody (1999-02-02),
13. 5830470 - Humanized antibodies to ganglioside GM.sub.2 (1998-11-03),
14. 5807548 - Method of treating cancer using a chimera antibody (1998-09-15),
15. 5750078 - Process for producing humanized chimera antibody (1998-05-12),

Title: Mamoru Hasegawa: Innovator in Cancer Treatment

Introduction

Mamoru Hasegawa is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development of humanized chimeric antibodies. With a total of 18 patents to his name, Hasegawa's work has the potential to impact the lives of many patients battling cancer.

Latest Patents

Hasegawa's latest patents include a method of treating cancer that involves administering a human chimeric antibody specific for the ganglioside GD3. This includes a humanized chimera antibody, a pharmaceutical composition comprising this antibody, and a method of treating cancer that involves administering a pharmaceutically acceptable amount of the humanized chimera antibody. Additionally, he has developed a process for producing the humanized chimera antibody, which is crucial for the pharmaceutical composition and treatment methods he has patented.

Career Highlights

Throughout his career, Hasegawa has worked with notable companies such as Kyowa Hakko Kogyo Co., Ltd. and Kyowa Medex Co., Ltd. His experience in these organizations has allowed him to refine his expertise in antibody development and cancer treatment methodologies.

Collaborations

Hasegawa has collaborated with esteemed colleagues, including Nobuo Hanai and Kenya Shitara. These partnerships have further enhanced his research and contributed to the advancement of innovative cancer therapies.

Conclusion

Mamoru Hasegawa's contributions to cancer treatment through his patents and collaborations highlight his dedication to improving patient outcomes. His innovative approaches in developing humanized chimeric antibodies are paving the way for new therapeutic options in oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…